Skip to main content

Table 4 Comparison basic clinical characteristics and outcomes of patient not treated by MTX or treated by MTX

From: Management of Caesarean scar pregnancy with or without methotrexate before curettage: human chorionic gonadotropin trends and patient outcomes

 

Mean ± SD/Rate

P value

Not treated by MTX (n = 47)

treated by MTX (n = 60)

 

Age (years)

32.04 ± 6.283

31.85 ± 5.544

0.867

Gestational age at diagnosis (days)

52.68 ± 11.664

49.37 ± 10.096

0.119

Fetal heart beat positive, n (%)

15(31.9%)

26(43.3%)

0.299

B:After MTX treatment or before curettage (mIU/ml)

31,163.48 ± 28,626.86

52,841.27 ± 41,148.83

0.003

C:Three days after curettage (mIU/ml)

2838.68 ± 3.10

4161.63 ± 4.52

0.090

C/B

0.085 ± 0.04

0.082 ± 0.05

0.856

Intraoperative blood loss (ml)

39.83 ± 16.96

52.37 ± 40.2

0.051

Pregnancy tissue retained, n (%)

1(2.1%)

3(5.0%)

0.437

Hospital stay (days)

7.00 ± 2.29

10.58 ± 3.35

<0.001